Dr. Timothy Wilkin

A large clinical trial among people living with HIV has found that treating anal precancerous lesions cuts the risk of developing anal cancer by 57 percent compared with active monitoring with no treatment.

As doctors face the novel coronavirus that causes COVID-19 with a very limited arsenal of treatments, physicians at Weill Cornell Medicine and NewYork-Presbyterian have rapidly mobilized to test candidate drugs in clinical trials.

With the goal of advancing the fight against COVID-19, the Partners of Citadel and Citadel Securities have made a $2 million gift to Weill Cornell Medicine to develop new approaches to protect people from the disease and identify new cases of it.

Weill Cornell Medicine, in collaboration with the Moffitt Cancer Center in Tampa, Florida and the Universidade de São Paulo in Brazil, has been awarded a five-year, $8.3 million grant from the National Cancer Institute to investigate ways to prevent human papillomavirus (HPV)-related cancers in people living with human immunodeficiency virus (HIV) infection.